CRYOLIFE, INC. (NYSE:CRY) Files An 8-K Submission of Matters to a Vote of Security HoldersItem 5.07
Submission of Matters to a Vote of Security Holders
CRYOLIFE, INC. (NYSE:CRY) Files An 8-K Submission of Matters to a Vote of Security Holders
At CryoLife, Inc.’s (the “Company” or “CryoLife”) 2018 Annual Meeting of Stockholders held on May 23, 2018 (the “Annual Meeting”), CryoLife’s stockholders elected each individual that was nominated for election as director of the Company to serve until the next annual meeting or until their successors are elected and have been qualified. The stockholders also (i) approved, by non-binding vote, the compensation paid to CryoLife’s named executive officers, as disclosed to Item 402 of Regulation S-K, including the Compensation Discussion and Analysis, compensation tables and narrative discussion, (ii) approved the addition of 1.9 million shares to the CryoLife, Inc. Equity and Cash Incentive Plan, and (iii) ratified the selection of Ernst & Young LLP as the independent registered public accounting firm for the Company for the year ending December 31, 2018.
The final results of the voting on each matter of business at the 2018 Annual Meeting are as follows:
Election of Directors
|
Name |
Votes For |
Votes Withheld |
Broker Non-Votes |
|
Thomas F. Ackerman |
29,795,524 | 662,581 | 4,331,078 |
|
Daniel J. Bevevino |
29,052,513 | 1,405,592 | 4,331,078 |
|
James W. Bullock |
30,015,966 | 442,139 | 4,331,078 |
|
Jeffrey H. Burbank |
30,252,874 | 205,231 | 4,331,078 |
|
J. Patrick Mackin |
30,032,297 | 425,808 | 4,331,078 |
|
Ronald D. McCall, Esq. |
27,301,439 | 3,156,666 | 4,331,078 |
|
Harvey Morgan |
30,124,944 | 333,161 | 4,331,078 |
|
Jon W. Salveson |
27,584,336 | 2,873,769 | 4,331,078 |
Approval, by non-binding vote of the compensation paid to CryoLife’s named executive officers, as disclosed to Item 402 of Regulation S-K, including the Compensation Discussion and Analysis, compensation tables and narrative discussion.
|
Votes For |
Votes Against |
Votes Abstain |
Broker Non-Votes |
|
26,017,748 |
4,274,332 |
166,025 |
4,331,078 |
Approval of the addition of 1.9 million shares to the CryoLife, Inc. Equity and Cash Incentive Plan.
|
Votes For |
Votes Against |
Votes Abstain |
Broker Non-Votes |
|
25,612,584 |
4,653,867 |
191,654 |
4,331,078 |
Ratification of the selection of Ernst & Young LLP as the independent registered public accounting firm for the Company for the year ending December 31, 2018.
|
Votes For |
Votes Against |
Votes Abstain |
|
34,289,633 |
481,979 |
17,571 |
About CRYOLIFE, INC. (NYSE:CRY)
CryoLife, Inc. (CryoLife) is engaged in medical device manufacturing and distribution, and in the processing and distribution of implantable human tissues for cardiac and vascular surgeries. The Company operates in two segments: Medical Devices and Preservation Services. The Medical Devices segment sells BioGlue, BioFoam, PerClot, CardioGenesis cardiac laser therapy, Hemodialysis Reliable Outflow (HeRO) Graft, and ProCol Vascular Bioprosthesis (ProCol). The Preservation Services segment preserves cardiac and vascular tissues. The Company’s surgical sealants and hemostats include BioGlue Surgical Adhesive (BioGlue), BioFoam Surgical Matrix (BioFoam), and PerClot, an absorbable powdered hemostat, which the Company distributes internationally for Starch Medical, Inc. (SMI). Its CardioGenesis cardiac laser therapy product line includes a laser console system and single-use, fiber-optic handpieces.
